Loss of PTPRS elicits potent metastatic capability and resistance to temozolomide in glioblastoma

Glioblastoma (GBM) is the most aggressive brain tumor type with worse clinical outcome due to the hallmarks of strong invasiveness, high rate of recurrence, and therapeutic resistance to temozolomide (TMZ), the first‐line drug for GBM, representing a major challenge for successful GBM therapeutics....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular carcinogenesis 2024-07, Vol.63 (7), p.1235-1247
Hauptverfasser:	Zhang, Yihua, Chang, Liugang, Huang, Ping, Cao, Min, Hong, Rujun, Zhao, Xinhu, He, Xuzhi, Xu, Lunshan
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents, Alkylating - pharmacology Antineoplastic Agents, Alkylating - therapeutic use Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain tumors Cancer therapies Cell Line, Tumor Cell Movement - drug effects Cell proliferation Cell Proliferation - drug effects chemoresistance Clinical outcomes Drug Resistance, Neoplasm - drug effects Gene Expression Regulation, Neoplastic - drug effects Glioblastoma Glioblastoma - drug therapy Glioblastoma - genetics Glioblastoma - metabolism Glioblastoma - pathology Glioma Humans Invasiveness MAP kinase Matrix metalloproteinase Metastases Metastasis Mice Mutation Phenotypes Protein phosphatase Protein-tyrosine-phosphatase PTPRS Receptor-Like Protein Tyrosine Phosphatases, Class 2 - genetics Receptor-Like Protein Tyrosine Phosphatases, Class 2 - metabolism Temozolomide Temozolomide - pharmacology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!